Mehmet Kosoglu joins AI/ML Innovations

AI/ML Innovations said September 1 that its wholly owned subsidiary, NeuralCloud Solutions, appointed Dr. Mehmet A. Kosoglu as head of regulatory affairs for its cardiac AI products. The company said Kosoglu is a former U.S. Food and Drug Administration lead reviewer and scientist with more than 15 years of experience across medical devices, Software as a Medical Device, digital health, diagnostics and combination products. (aiml-innovations.com) In the role, he will support regulatory strategy for NeuralCloud’s MaxYield and CardioYield platforms, according to the company’s release. The appointment lands as FDA continues to expand and update its public materials for AI-enabled medical devices and software as a medical device. The agency says its AI-enabled medical device list is intended to identify devices authorized for marketing in the United States, while separate FDA guidance and draft guidance outline lifecycle management, marketing submission recommendations and change-control planning for AI-enabled device software functions. (fda.gov) ### Who is Mehmet Kosoglu, and what exactly was announced? Dr. Mehmet A. Kosoglu was named head of regulatory affairs at NeuralCloud Solutions, the AI/ML Innovations subsidiary said in the September 1 announcement. The company described him as a senior regulatory affairs executive and former FDA lead reviewer whose background includes medical device development, biotechnology, FDA regulations, SaMD, digital health and diagnostics. (aiml-innovations.com) Yahoo Finance’s republication of the company statement said the hire is meant to support AIML’s medical device strategy. The release also tied Kosoglu directly to the company’s cardiac technology programs rather than a broader corporate compliance role. (fda.gov) ### What products will he work on inside NeuralCloud? NeuralCloud said Kosoglu will support its regulatory strategy for MaxYield and CardioYield. AI/ML Innovations has previously described those offerings in investor materials and press releases as part of its AI-driven cardiac technology portfolio. An August 18 company release said NeuralCloud had signed a term sheet with Island Mobile Cardiology Testing for a CardioYield pilot. (aiml-innovations.com) Earlier company updates also referenced deployments or pilots involving MaxYield in wellness, athlete monitoring and pediatric cardiac care settings. ### Why does a former FDA reviewer matter for a cardiac AI company? FDA says AI-enabled medical devices are already being authorized for marketing in the United States and that manufacturers can use the agency’s public list to understand the current device landscape and regulatory expectations. (finance.yahoo.com) The agency also says AI technologies in medical devices require careful management across the total product life cycle. The January 2025 FDA draft guidance on AI-enabled device software functions lays out recommendations for marketing submissions, and FDA’s devices guidance index shows a 2025 guidance on predetermined change control plans for AI-enabled device software functions. (aiml-innovations.com) Those documents are relevant to companies developing software products that may need to show how models are managed, updated and documented over time. (aiml-innovations.com) ### How does this fit with AI/ML Innovations’ recent hiring and certification moves? AI/ML Innovations has added other regulatory and clinical leadership over the past two years. A January 2025 release said the company appointed Andrea Ruth as head of quality, clinical and regulatory affairs, and a February 2026 release said it named Dr. (fda.gov) Paul Dorian as medical innovation architect and head of its medical advisory board. On August 11, 2026, the company said NeuralCloud achieved ISO 13485:2016 certification under MDSAP, a quality-management milestone commonly used in medical device operations. That certification came weeks before the Kosoglu appointment and before the company disclosed the CardioYield pilot term sheet. (fda.gov) ### What comes next for NeuralCloud’s cardiac AI programs? AI/ML Innovations’ investor page lists an August 18, 2026 announcement on the Island Mobile Cardiology Testing term sheet for a CardioYield pilot, indicating one near-term commercial and validation step already underway. The same investor archive shows multiple earlier pilot and deployment announcements tied to MaxYield and CardioYield. FDA’s current AI-enabled device materials remain the public reference point for companies moving software-based medical products toward U.S. authorization. (aiml-innovations.com) For NeuralCloud, the next visible milestones are likely to come through future pilot updates, submission-related disclosures or additional product notices tied to MaxYield and CardioYield. (fda.gov) (aiml-innovations.com)